HPV screening in the urine of transpeople - A prevalence study

Sophie Pils, Jana Mlakar, Mario Poljak, Grega Gimpelj Domjanič, Ulrike Kaufmann, Stephanie Springer, Andreas Salat, Eva Langthaler, Elmar A Joura, Sophie Pils, Jana Mlakar, Mario Poljak, Grega Gimpelj Domjanič, Ulrike Kaufmann, Stephanie Springer, Andreas Salat, Eva Langthaler, Elmar A Joura

Abstract

Background: There is limited data on human papillomaviruses (HPV) prevalence in transpeople due to low acceptance rate of screening methods. HPV tests from self-collected urine are gender-neutral, have a high acceptance, and have a comparable accuracy in females to clinician-collected samples. The aim of this study was to evaluate both the HPV prevalence in the urine in a large cohort of 200 transpeople with common risk profiles and the acceptability of such screening method.

Methods: The study was conducted at the outpatient clinic for transpeople at the Department of Obstetrics and Gynaecology, Medical University of Vienna, Austria. 200 transpeople have been enrolled between May and October 2021. Inclusion criteria were gender identity dysphoria, age over 18 years, and adequate language skills.Subjects were asked to answer a survey concerning gender identity, established risk factors for HPV infections as well as their preference regarding urine or provider-collected cytology-/HPV-based screening, and to provide a urine sample. Five patients not able to provide urine were excluded. HPV genotyping was performed using a validated multiplex real-time PCR assay, which simultaneously detects 28 HPV genotypes. This trial is registered at ClinicalTrials.gov, NCT04864951.

Findings: Overall HPV positivity was 19·0% (37/195), 24·2% in female to male, 11·8% in male to female, 26·3% in genderqueer/non binary/other subjects, 27·9% in subjects currently having a cervix, and 26·0% in subjects born with cervix. Independent of gender reassignment surgery, being born with a cervix was associated with a higher risk of HPV infections (p = 0·008), yet 42·3% (44/104) have never attended cervical cancer screening. Overall, 79·0% (154/195) of transpeople would prefer urine HPV tests to provider-collected HPV screening.

Interpretation: HPV testing in self-collected urine samples provides a unique opportunity for screening of this hard-to-reach population and should be evaluated in further studies.

Funding: None.

Keywords: FtM; HPV prevalence; MtF; Non binary; Transgender; Transpeople.

Conflict of interest statement

Elmar A. Joura reports advisory board fees, lecture fees and grants from Merck, and advisory board fees and lecture fees from Roche Diagnostics all outside of this study. Sophie Pils reports lecture fees from Merck outside of this study. Jana Mlakar, Mario Poljak, Grega Gimpelj Domjanič, Ulrike Kaufmann, Stephanie Springer, Andreas Salat, and Eva Langthaler report no conflict of interest.

© 2022 The Author(s).

Figures

Figure 1
Figure 1
Flow diagram.

References

    1. Bosch FX, Broker TR, Forman D, et al. Comprehensive control of HPV infections and related diseases. Vaccine. 2013;31(8):I1–31.
    1. de Sanjosé S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49(16):3450–3461.
    1. Castellsagué X, Alemany L, Quer M, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst. 2016;108(6):djv403.
    1. Wang G, Ferguson D, Ionescu DN, et al. HPV-related neovaginal squamous cell carcinoma presenting as lung metastasis after male-to-female gender confirmation surgery. Case Rep Oncol. 2020;13(1):17–22.
    1. Alemany L, Cubilla A, Halec G, et al. Role of human papillomavirus in penile carcinomas worldwide. Eur Urol. 2016;69(5):953–961.
    1. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–532.
    1. Reisner SL, Deutsch MB, Peitzmeier SM, et al. Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients. PLoS One. 2018;13(3)
    1. Loverro G, Di Naro E, Caringella AM, De Robertis AL, Loconsole D, Chironna M. Prevalence of human papillomavirus infection in a clinic sample of transsexuals in Italy. Sex Transm Infect. 2016;92(1):67–69.
    1. van der Sluis WB, Buncamper ME, Bouman MB, et al. Prevalence of neovaginal high-risk human papillomavirus among transgender women in the Netherlands. Sex Transm Dis. 2016;43(8):503–505.
    1. Cranston RD, Carballo-Diéguez A, Gundacker H, et al. Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender women. Int J STD AIDS. 2019;30(2):154–162.
    1. Singh V, Gratzer B, Gorbach PM, et al. Transgender women have higher human papillomavirus prevalence than men who have sex with men—two U.S. cities, 2012–2014. Sex Transm Dis. 2019;46(10):657–662.
    1. Rollston R. The Fenway Institute; 2019. Promoting Cervical Cancer Screening Among Female-to-Male Transmasculine Patients. 2022-06-19.
    1. McDowell M, Pardee DJ, Peitzmeier S, et al. Cervical cancer screening preferences among trans-masculine individuals: patient-collected human papillomavirus vaginal swabs versus provider-administered pap tests. LGBT Health. 2017;4(4):252–259.
    1. Peitzmeier SM, Khullar K, Reisner SL, Potter J. Pap test use is lower among female-to-male patients than non-transgender women. Am J Prev Med. 2014;47(6):808–812.
    1. Thoma BC, Rezeppa TL, Choukas-Bradley S, Salk RH, Marshal MP. Disparities in childhood abuse between transgender and cisgender adolescents. Pediatrics. 2021;148(2)
    1. Cho H-W, Shim SR, Lee JK, Hong JH. Accuracy of human papillomavirus tests on self-collected urine versus clinician-collected samples for the detection of cervical precancer: a systematic review and meta-analysis. J Gynecol Oncol. 2022;33(1):e4.
    1. De Pauw H, Donders G, Weyers S, et al. Cervical cancer screening using HPV tests on self-samples: attitudes and preferences of women participating in the VALHUDES study. Arch Public Health. 2021;79(1):155.
    1. Giuliano AR, Nielson CM, Flores R, et al. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis. 2007;196(8):1146–1152.
    1. Franceschi S, Chantal Umulisa M, Tshomo U, et al. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. Int J Cancer. 2016;139(3):518–526.
    1. Jiamsiri S, Rhee C, Ahn HS, et al. A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand. PLoS One. 2022;17(4)
    1. Eklund C, Mühr LSA, Lagheden C, Forslund O, Robertsson KD, Dillner J. The 2019 HPV Labnet international proficiency study: need of global Human Papillomavirus Proficiency Testing. J Clin Virol. 2021;141
    1. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–1799.
    1. Brown B, Galea JT, Byraiah G, et al. Anogenital human papillomavirus infection and HIV infection outcomes among Peruvian transgender women: results from a cohort study. Transgend Health. 2016;1:94–98.
    1. Jalil EM, Wilson EC, Monteiro L, et al. High prevalence of anal high-risk HPV infection among transwomen: estimates from a Brazilian RDS study. J Int AIDS Soc. 2021;24(3):e25691.
    1. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study. Sex Transm Dis. 2011;38(10):932–940.
    1. Martín-Ezquerra G, Fuste P, Larrazabal F, et al. Incidence of human papillomavirus infection in male sexual partners of women diagnosed with CIN II-III. Eur J Dermatol. 2012;22(2):200–204.
    1. Schmid BC, Pils S, Heinze G, Hefler L, Reinthaller A, Speiser P. Forced coughing versus local anesthesia and pain associated with cervical biopsy: a randomized trial. Am J Obstet Gynecol. 2008;199(6) 641.e1-3.
    1. Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening. J Gen Intern Med. 2014;29(5):778–784.
    1. Stevens-Simon C, Nelligan D, Breese P, Jenny C, Douglas JM., Jr The prevalence of genital human papillomavirus infections in abused and nonabused preadolescent girls. Pediatrics. 2000;106(4):645–649.
    1. Alcalá HE, Keim-Malpass J, Mitchell EM. Sexual assault and cancer screening among men and women. J Interpers Violence. 2021;36(11-12):NP6243–NP6259.
    1. Garland SM, Subasinghe AK, Jayasinghe JL, Wark JD, Moscicki A-M, Singer A, Bosch X, Cusack K, Stanley M. HPV vaccination for victims of childhood sexual abuse. Lancet. 2015;386(10007):1919–1920.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa